Ultragenyx Pharmaceutical Inc. (RARE) 주식 분석

회사 개요

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to the identification, acquisition, development, and commercialization of novel therapeutic products for rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. The company operates within the healthcare sector, specifically the biotechnology industry, which focuses on the discovery and production of advanced biological medicines to treat conditions that typically affect a small number of patients. As of the latest data, Ultragenyx holds a market capitalization of $2.28B and employs 1,371 individuals, with annual revenue reaching $673.00M based on trailing twelve-month figures. These valuation and revenue metrics position Ultragenyx as a mid-cap entity with a significant operational footprint, indicating substantial scale in the specialized rare disease market despite the high costs associated with R&D and commercialization in this niche sector.

재무 건전성

The company reported revenue of $673.00M over the trailing twelve months, yet it recorded a net income of -$575,000,000 and an EBITDA of -$500,000,000, revealing a cost structure where expenses significantly exceed operational cash generation. The free cash flow stands at -$251,124,992, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations entirely from internal cash flows without external capital injection. When analyzing profitability margins, the gross margin is reported at -27.6%, the operating margin at -54.7%, and the profit margin at -85.4%, all of which indicate that the company is operating at a loss at every level of its income statement, a common characteristic in the early-to-mid stages of biotechnology development where R&D and marketing expenditures are front-loaded. The balance sheet shows cash reserves of $680.00M against total debt of $1.25B, while the debt-to-equity ratio is listed as N/A, suggesting that the firm relies more on equity or other financing methods than traditional debt leverage. Despite the high debt absolute value, the current ratio of 2.48 indicates a strong short-term liquidity position, meaning the company holds sufficient current assets to cover its short-term liabilities comfortably. Furthermore, the return on equity is -608.5% and the return on assets is -22.0%, metrics that reveal management is currently not generating positive returns on the capital invested in the business, reflecting the inherent risks and high capital requirements of the biotechnology industry.

밸류에이션 평가

The valuation metrics show a trailing P/E ratio of N/A due to the negative earnings, while the forward P/E is listed at 286.12, a stark difference that implies the market is pricing in significant future earnings growth or a potential turnaround in profitability that does not yet exist in the current financials. The price-to-book ratio stands at -27.89, indicating a negative relationship between market value and book value, which is typical for biotech firms with intangible assets like intellectual property that are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 3.38 and an EV/EBITDA of -5.62 suggest that investors are valuing the company primarily on its revenue potential and asset base rather than current profitability. The stock has a 52-week high of $42.37 and a 52-week low of $18.29, placing the current trading price within this volatility range and reflecting the speculative nature of the stock price relative to the broader market. The beta value is 0.25, which indicates that the stock price is significantly less volatile than the broader market, moving less than a quarter of the market's magnitude during periods of price fluctuation.

Growth & Income

Ultragenyx demonstrates a revenue growth year-over-year of 25.9%, whereas earnings growth is listed as N/A due to the lack of positive earnings, implying that top-line expansion is currently the primary driver of value rather than profit growth. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings to reinvest into research and development rather than distributing income to shareholders. Given the negative net income, a dividend payout is not feasible or sustainable, reinforcing the strategy of capital allocation toward growth initiatives and product commercialization. Overall, the growth and income profile of Ultragenyx Pharmaceutical Inc. is characterized by strong revenue expansion coupled with a complete reinvestment of capital, resulting in negative earnings and no income distribution to investors.